Patents by Inventor Wadih Arap

Wadih Arap has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240115722
    Abstract: The present invention relates in certain aspects to antibodies, binding polypeptides, and immunoconjugates specific for human EPH receptor A5 (EphA5).
    Type: Application
    Filed: July 27, 2023
    Publication date: April 11, 2024
    Applicants: Rutgers, The State University of New Jersey, MBrace Therapeutics, Inc.
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda I. Staquicini
  • Publication number: 20240050580
    Abstract: In one aspect, the present disclosure relates to tumor associated macrophage (TAM) targeting peptide. In another aspect, the present disclosure relates to a method of targeting a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle. In yet another aspect, the present disclosure relates to a method of treating a tumor infiltrated with a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle.
    Type: Application
    Filed: December 20, 2021
    Publication date: February 15, 2024
    Applicants: Rutgers, The State University of New Jersey, Board of Regents, The University of Texas System
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda I. Staquicini, Amin Hajitou, Wouter Driessen, Daniela Staquicini, Bettina Proneth
  • Publication number: 20230293710
    Abstract: The present invention relates in certain aspects to antibodies, binding polypeptides, and immunoconjugates specific for human EPH receptor A5 (EphA5).
    Type: Application
    Filed: November 3, 2022
    Publication date: September 21, 2023
    Applicants: Rutgers, The State University of New Jersey, MBrace Therapeutics, Inc.
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda I. Staquicini
  • Publication number: 20230241203
    Abstract: The present disclosure includes an immunogenic composition comprising an effective amount of a therapeutic engineered phage and a pharmaceutically acceptable carrier. In certain aspects, the disclosure includes a method of stimulating an immune response in a subject comprising administering to the subject a composition comprising an effective amount of a therapeutic engineered phage. In certain aspects, the disclosure includes a method for treating, ameliorating, and/or preventing a coronavirus infection in a subject comprising administering a composition comprising an effective amount of a therapeutic engineered phage.
    Type: Application
    Filed: July 3, 2021
    Publication date: August 3, 2023
    Inventors: Renata Pasqualini, Wadih Arap, Steven Libutti, Christopher Markosian, Daniela Staquicini, Fenny Tang, Tracey Smith, Virginia Yao
  • Publication number: 20230139913
    Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Application
    Filed: October 18, 2022
    Publication date: May 4, 2023
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R.M. Bradbury
  • Publication number: 20230028927
    Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Application
    Filed: June 10, 2022
    Publication date: January 26, 2023
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R.M. Bradbury
  • Publication number: 20220354861
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Application
    Filed: November 30, 2021
    Publication date: November 10, 2022
    Inventors: Jimmy Andrew ROTOLO, Richard N. KOLESNICK, Renata PASQUALINI, Wadih ARAP
  • Publication number: 20220348680
    Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Application
    Filed: June 10, 2022
    Publication date: November 3, 2022
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R.M. Bradbury
  • Publication number: 20220332759
    Abstract: The present disclosure relates, in one aspect, to the identification of certain peptides that allow for transport of a solid particle across the air-blood barrier in the lungs. In certain embodiments, the solid particle comprises any sort of solid cargo to which the peptides contemplated in the disclosure can be attached.
    Type: Application
    Filed: October 1, 2020
    Publication date: October 20, 2022
    Inventors: Renata Pasqualini, Wadih Arap, Daniela Staquicini
  • Publication number: 20220306763
    Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Application
    Filed: February 4, 2022
    Publication date: September 29, 2022
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R.M. Bradbury
  • Patent number: 11254751
    Abstract: Isolated or recombinant Eph A5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: February 22, 2022
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R. M. Bradbury
  • Patent number: 11207329
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 28, 2021
    Assignees: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Patent number: 10844365
    Abstract: Systems and methods generally useful in medicine, cellular biology, nanotechnology, and cell culturing are discussed. In particular, at least in some embodiments, systems and methods for magnetic guidance and patterning of cells and materials are discussed. Some specific applications of these systems and methods may include levitated culturing of cells away from a surface, making and manipulating patterns of levitated cells, and patterning culturing of cells on a surface. Specifically, a method of culturing cells is presented. The method may comprise providing a plurality of cells, providing a magnetic field, and levitating at least some of the plurality of cells in the magnetic field, wherein the plurality of cells comprise magnetic nanoparticles. The method may also comprise maintaining the levitation for a time sufficient to permit cell growth to form an assembly.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: November 24, 2020
    Assignees: William Marsh Rice University, The Board of Regents of the University of Texas System
    Inventors: Glauco R. Souza, Renata Pasqualini, Wadih Arap, Thomas Charles Killian, Robert M. Raphael, Daniel Joshua Stark
  • Publication number: 20190202922
    Abstract: Isolated or recombinant Eph A5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vim methodologies is also provided.
    Type: Application
    Filed: September 21, 2017
    Publication date: July 4, 2019
    Inventors: RENATA PASQUALINI, WADIH ARAP, FERNANDA IAMASSAKA STAQUICINI, FORTUNATO FERRARA, ANDREW R.M. BRADBURY
  • Publication number: 20190046538
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Application
    Filed: February 27, 2018
    Publication date: February 14, 2019
    Applicants: Sloan Kettering Institute for Cancer Research, Board of Regents, The University of Texas System
    Inventors: Jimmy Andrew ROTOLO, Richard N. KOLESNICK, Renata PASQUALINI, Wadih ARAP
  • Publication number: 20180265858
    Abstract: Systems and methods generally useful in medicine, cellular biology, nanotechnology, and cell culturing are discussed. In particular, at least in some embodiments, systems and methods for magnetic guidance and patterning of cells and materials are discussed. Some specific applications of these systems and methods may include levitated culturing of cells away from a surface, making and manipulating patterns of levitated cells, and patterning culturing of cells on a surface. Specifically, a method of culturing cells is presented. The method may comprise providing a plurality of cells, providing a magnetic field, and levitating at least some of the plurality of cells in the magnetic field, wherein the plurality of cells comprise magnetic nanoparticles. The method may also comprise maintaining the levitation for a time sufficient to permit cell growth to form an assembly.
    Type: Application
    Filed: March 5, 2018
    Publication date: September 20, 2018
    Inventors: Glauco R. SOUZA, Renata Pasqualini, Wadih ARAP, Thomas Charles KILLIAN, Robert M. RAPHAEL, Daniel Joshua STARK
  • Publication number: 20180256740
    Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.
    Type: Application
    Filed: October 23, 2017
    Publication date: September 13, 2018
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Renata PASQUALINI, Wadih ARAP, Juri GELOVANI, Frank C. MARINI, III, Amin HAJITOU, Mian ALAUDDIN, Martin TREPEL
  • Patent number: 9909116
    Abstract: Systems and methods generally useful in medicine, cellular biology, nanotechnology, and cell culturing are discussed. In particular, at least in some embodiments, systems and methods for magnetic guidance and patterning of cells and materials are discussed. Some specific applications of these systems and methods may include levitated culturing of cells away from a surface, making and manipulating patterns of levitated cells, and patterning culturing of cells on a surface. Specifically, a method of culturing cells is presented. The method may comprise providing a plurality of cells, providing a magnetic field, and levitating at least some of the plurality of cells in the magnetic field, wherein the plurality of cells comprise magnetic nanoparticles. The method may also comprise maintaining the levitation for a time sufficient to permit cell growth to form an assembly.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: March 6, 2018
    Assignee: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Glauco R Souza, Renata Pasqualini, Wadih Arap, Thomas Charles Killian, Robert M. Raphael, Daniel Joshua Stark
  • Patent number: 9827327
    Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: November 28, 2017
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Renata Pasqualini, Wadih Arap, Juri Gelovani, Frank C. Marini, III, Amin Hajitou, Mian Alauddin, Martin Trepel
  • Publication number: 20170273987
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Application
    Filed: February 20, 2017
    Publication date: September 28, 2017
    Applicants: Sloan Kettering Institute for Cancer Research, Board of Regents, The University of Texas System
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap